Metallic stent placement for XXXX .

@entity1 @entity1353 @entity5 @entity75 @entity2 @entity256 @entity850
The purpose of this study was to evaluate the utility of metallic stents for treating central airway @entity850 caused by @entity5 . The subjects were 72 @entity1 (16 @entity1 , 56 @entity1 ; mean age, 61 years; age range, 28-87 years) treated with metallic stents for @entity1353 due to @entity75 caused by @entity5 between May 1990 and August 2010. The underlying disorder was @entity2 in 42 @entity1 , metastatic @entity2 in 29, and @entity5 in one @entity1 . In 69 of 72 @entity1 (95.8%), @entity1353 began to improve following completion of the procedure. The average Hugh-Jones classification score improved from 4.2 before stenting to 2.8 after stenting. The @entity1 ' average survival following stent placement was 3.6 months (two days-33 months). Thirteen lesions developed re-obstruction during follow-up. Of these 13 lesions, eight @entity1 with @entity1353 underwent re-interventions with metallic stent replacement and improved. Airway stent placement is an immediate and effective method of treatment for @entity1353 caused by stenotic lesions of the central airway due to @entity5 . It is effective for treating @entity850 due to either @entity5 or extrinsic compression. Restenting is also useful to treat @entity1353 caused by @entity256 following stent placement.
